Cost-utility analysis of a multicomponent intervention for fibromyalgia syndrome in primary care versus usual clinical practice: study protocol for an economic evaluation of a randomised control trial

Victoria Mailen Arfuch, Carina Aguilar Martín, Anna Berenguera, Rosa Caballol Angelats, Noèlia Carrasco-Querol, Gemma González Serra, Maria Cinta Sancho Sol, Immaculada Fusté Anguera, José Fernández Sáez, Alessandra Queiroga Gonçalves, Marc Casajuana, Victoria Mailen Arfuch, Carina Aguilar Martín, Anna Berenguera, Rosa Caballol Angelats, Noèlia Carrasco-Querol, Gemma González Serra, Maria Cinta Sancho Sol, Immaculada Fusté Anguera, José Fernández Sáez, Alessandra Queiroga Gonçalves, Marc Casajuana

Abstract

Introduction: Fibromyalgia syndrome (FMS) imposes a high cost on society. The significant economic burden from the use of healthcare and, especially, social resources is a spur to revising the usual clinical care (UCC) and to improving treatment strategies. FMS has a deleterious effect on the quality of life (QOL) and productivity, which considerably increase the indirect costs to society. This study reports an economic evaluation comparing the cost and health benefits in a multicomponent intervention programme and UCC of patients with FMS who attend primary healthcare centres of the Gerència Territorial Terres de L'Ebre region of Catalonia, Spain. This article is linked to the pre-results of a randomised control trial study on the implementation of this intervention programme (ClinicalTrials.gov: NCT04049006).

Method and analysis: A cost-utility analysis will be conducted from a societal perspective. Quality-adjusted life years will be calculated from the results of the SF-36 questionnaire, a QOL measurement instrument. Direct and indirect healthcare costs will be obtained from official prices and reports published by the Spanish Public Health Administration and the National Statistics Institute. The incremental cost-utility ratio will be estimated to compare the two healthcare practices. Deterministic sensitivity analysis will also be used to compare different cost scenarios, modifying the items with the highest weight in the cost composition.

Ethics and dissemination: The Clinical Research Ethics Committee of the IDIAPJGol Institute approved this study on 25 April 2018 (code P18/068) in accordance with the Helsinki/Tokyo Declaration. Information will be provided orally and in writing to participants, and their informed consent will be required. Participant anonymity will be guaranteed. The dissemination strategy includes publications in scientific journals and presentations in local and national media and at academic conferences. Trial registration number: NCT04049006; Pre-results.

Keywords: health economics; primary care; public health; rheumatology.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

References

    1. Wolfe F, Smythe HA, Yunus MB, et al. . The American College of rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria Committee. Arthritis Rheum 1990;33:160–72. 10.1002/art.1780330203
    1. Wolfe F, Clauw DJ, Fitzcharles M-A, et al. . Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR preliminary diagnostic criteria for fibromyalgia. J Rheumatol 2011;38:1113–22. 10.3899/jrheum.100594
    1. Wolfe F, Clauw DJ, Fitzcharles M-A, et al. . 2016 revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum 2016;46:319–29. 10.1016/j.semarthrit.2016.08.012
    1. Helfenstein M, Goldenfum MA, Siena CAF. Fibromyalgia: clinical and occupational aspects. Rev Assoc Med Bras 2012;58:358–65.
    1. Skaer TL. Fibromyalgia: disease synopsis, medication cost effectiveness and economic burden. Pharmacoeconomics 2014;32:457–66. 10.1007/s40273-014-0137-y
    1. Marques AP, Santo AdeSdoE, Berssaneti AA, et al. . Prevalence of fibromyalgia: literature review update. Rev Bras Reumatol Engl Ed 2017;57:356–63. 10.1016/j.rbre.2017.01.005
    1. Seoane-Mato D, Sánchez-Piedra C, Silva-Fernández L, et al. . Prevalence of rheumatic diseases in adult population in Spain (EPISER 2016 study): aims and methodology. Reumatol Clin 2019;15:90–6. 10.1016/j.reuma.2017.06.009
    1. Robinson RL, Birnbaum HG, Morley MA, et al. . Economic cost and epidemiological characteristics of patients with fibromyalgia claims. J Rheumatol 2003;30:1318–25.
    1. Epidemiology SM. Costs, and the economic burden of fibromyalgia. Arthritis Res Ther 2009;11:2–3.
    1. Sicras-Mainar A, Rejas J, Navarro R, et al. . Treating patients with fibromyalgia in primary care settings under routine medical practice: a claim database cost and burden of illness study. Arthritis Res Ther 2009;11:1–14. 10.1186/ar2673
    1. Rivera J, Rejas J, Esteve-Vives J, et al. . Resource utilisation and health care costs in patients diagnosed with fibromyalgia in Spain. Clin Exp Rheumatol 2009;27:S39–45.
    1. Thompson JM, Luedtke CA, Oh TH, et al. . Direct medical costs in patients with fibromyalgia: cost of illness and impact of a brief multidisciplinary treatment program. Am J Phys Med Rehabil 2011;90:40–6. 10.1097/PHM.0b013e3181fc7ff3
    1. Vervoort VM, Vriezekolk JE, Olde Hartman TC, et al. . Cost of illness and illness perceptions in patients with fibromyalgia. Clin Exp Rheumatol 2016;34:S74–82.
    1. White KP, Speechley M, Harth M, et al. . The London fibromyalgia epidemiology study: direct health care costs of fibromyalgia syndrome in London, Canada. J Rheumatol 1999;26:885–9.
    1. Berger A, Dukes E, Martin S, et al. . Characteristics and healthcare costs of patients with fibromyalgia syndrome. Int J Clin Pract 2007;61:1498–508. 10.1111/j.1742-1241.2007.01480.x
    1. Berger A, Sadosky A, Dukes EM, et al. . Patterns of healthcare utilization and cost in patients with newly diagnosed fibromyalgia. Am J Manag Care 2010;16:S126–37.
    1. Boonen A, van den Heuvel R, van Tubergen A, et al. . Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosing spondylitis. Ann Rheum Dis 2005;64:396–402. 10.1136/ard.2003.019711
    1. Winkelmann A, Perrot S, Schaefer C, et al. . Impact of fibromyalgia severity on health economic costs. Appl Health Econ Health Policy 2011;9:125–36. 10.2165/11535250-000000000-00000
    1. Feliu-Soler A, Borràs X, Peñarrubia-María MT, et al. . Cost-Utility and biological underpinnings of Mindfulness-Based stress reduction (MBSR) versus a psychoeducational programme (FibroQoL) for fibromyalgia: a 12-month randomised controlled trial (EUDAIMON study). BMC Complement Altern Med 2016;16:1–16. 10.1186/s12906-016-1068-2
    1. Cabo-Meseguer A, Cerdá-Olmedo G, Trillo-Mata JL. Fibromyalgia: prevalence, epidemiologic profiles and economic costs. Med Clin 2017;149:441–8. 10.1016/j.medcli.2017.06.008
    1. Instituto Nacional de la Seguridad social. Guia de actualización en La valoración de fibromialgia, sÍndrome de fatiga crónica, sensibilidad química múltiple Y electrosensibilidad. Segunda Edición 2019
    1. Chisholm D, Evans DB. Economic evaluation in health: saving money or improving care? J Med Econ 2007;10:325–37. 10.3111/13696990701605235
    1. Franklin M. Cost utility analysis. in: mental health economics: the costs and benefits of psychiatric care. Cham. Springer International Publishing 2017:89–119.
    1. Mccabe C. What is cost-utility analysis? Hayward Med Commun 2009:1–6
    1. Goossens ME, Rutten-van Mölken MP, Leidl RM, et al. . Cognitive-educational treatment of fibromyalgia: a randomized clinical trial. II. economic evaluation. J Rheumatol 1996;23:1246–54.
    1. Luciano JV, Sabes-Figuera R, Cardeñosa E, et al. . Cost-Utility of a psychoeducational intervention in fibromyalgia patients compared with usual care: an economic evaluation alongside a 12-month randomized controlled trial. Clin J Pain 2013;29:702–11. 10.1097/AJP.0b013e318270f99a
    1. Luciano JV, D’Amico F, Cerdà-Lafont M, et al. . Cost-Utility of cognitive behavioral therapy versus U.S. food and drug administration recommended drugs and usual care in the treatment of patients with fibromyalgia: an economic evaluation alongside a 6-month randomized controlled trial. Arthritis Res Ther 2014;16:1–17. 10.1186/s13075-014-0451-y
    1. Luciano JV, D'Amico F, Feliu-Soler A, et al. . Cost-Utility of group acceptance and commitment therapy for fibromyalgia versus recommended drugs: an economic analysis alongside a 6-month randomized controlled trial conducted in Spain (EFFIGACT study). J Pain 2017;18:868–80. 10.1016/j.jpain.2017.03.001
    1. Hedman-Lagerlöf M, Hedman-Lagerlöf E, Ljótsson B, et al. . Cost-Effectiveness and cost-utility of internet-delivered exposure therapy for fibromyalgia: results from a randomized, controlled trial. J Pain 2019;20:47–59. 10.1016/j.jpain.2018.07.012
    1. Pérez-Aranda A, D’Amico F, Feliu-Soler A, et al. . Cost–Utility of Mindfulness-Based stress reduction for fibromyalgia versus a multicomponent intervention and usual care: a 12-month randomized controlled trial (EUDAIMON study). JCM 2019;8:1068. 10.3390/jcm8071068
    1. D'Amico F, Feliu-Soler A, Montero-Marín J, et al. . Cost-Utility of Attachment-Based compassion therapy (ABCT) for fibromyalgia compared to relaxation: a pilot randomized controlled trial. J Clin Med 2020;9:726. 10.3390/jcm9030726
    1. Luciano JV, Martínez N, Peñarrubia-María MT, et al. . Effectiveness of a psychoeducational treatment program implemented in general practice for fibromyalgia patients: a randomized controlled trial. Clin J Pain 2011;27:383–91. 10.1097/AJP.0b013e31820b131c
    1. Celaya M, Ibáñez D, Laseca N. Guia per a l'avaluació de la fibromi lgia i de la síndrome de fatiga crònica. Generalitat de Catalunya, 2017. Available: [Accessed 20 Feb 2020].
    1. Caballol Angelats R, Gonçalves AQ, Aguilar Martín C, et al. . Effectiveness, cost-utility, and benefits of a multicomponent therapy to improve the quality of life of patients with fibromyalgia in primary care. Medicine 2019;98:e17289. 10.1097/MD.0000000000017289
    1. Caballol Angelats R, Gonçalves AQ, Aguilar Martín C, et al. . Effectiveness, cost-utility, and benefits of a multicomponent therapy to improve the quality of life of patients with fibromyalgia in primary care: a mixed methods study protocol. Medicine 2019;98:e17289. 10.1097/MD.0000000000017289
    1. Husereau D, Drummond M, Petrou S, et al. . Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health 2013;16:231–50. 10.1016/j.jval.2013.02.002
    1. Craig P, Dieppe P, Macintyre S, et al. . Developing and evaluating complex interventions: the new medical Research Council guidance. Int J Nurs Stud 2013;50:587–92. 10.1016/j.ijnurstu.2012.09.010
    1. Nishishinya Aquino B, Requeijo Lorenzo C, Roqué Fíguls M. Evaluación Y abordaje de la fibromialgia. Actualización de las evidencias científicas. Barcelona. Ministerio de Sanidad, Servicios Sociales e Igualdad. Agència de Qualitat i Avaluació Sanit ries de Catalunya. Departament de Salut. Generalitat de Catalunya 2017. (Informes de Evaluación de Tecnologías Sanitarias)
    1. Gándara M, Muñoz G. Evaluación Y abordaje de la fibromialgia Y El síndrome de fatiga crónica. Día Mundial de la Fibromialgia Y El Síndrome de Fatiga Crónica. Oficial Nacional de Salud Pública-AEMPPI Ecuador 2017
    1. Alonso J, et al. . Versión española de SF-36v2TM health survey © 1996, 2000, adapted by J. Alonso, et al. Heal Surv 2003:1–8
    1. Catalunya Gde. Diari Oficial de la Generalitat de Catalunya. Available:
    1. España Gde. Real Decreto 8/2015 POR El que Se aprueba El texto refundido de la Ley General de la Seguridad social. Boletín Oficial del Estado 2015:1–157
    1. Estadística INde. (ine). Coste laboral POR trabajador, comunidad autónoma, sectores de actividad. Available: [Accessed 20 Mar 2020].
    1. Andronis L, Barton P, Bryan S. Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making. Health Technol Assess 2009;13. 10.3310/hta13290
    1. Wang S-M, Han C, Lee S-J, et al. . Fibromyalgia diagnosis: a review of the past, present and future. Expert Rev Neurother 2015;15:667–79. 10.1586/14737175.2015.1046841
    1. Briones-Vozmediano E. The social construction of fibromyalgia as a health problem from the perspective of policies, professionals, and patients. Glob Health Action 2017;10:1275191. 10.1080/16549716.2017.1275191
    1. Lichtenstein A, Tiosano S, Amital H. The complexities of fibromyalgia and its comorbidities. Curr Opin Rheumatol 2018;30:94–100. 10.1097/BOR.0000000000000464
    1. Giusti EM, Castelnuovo G, Molinari E. Differences in multidisciplinary and interdisciplinary treatment programs for fibromyalgia: a mapping review. Pain Res Manag 2017;2017:1–19. 10.1155/2017/7261468
    1. Bourgault P, Lacasse A, Marchand S, et al. . Multicomponent interdisciplinary group intervention for self-management of fibromyalgia: a mixed-methods randomized controlled trial. PLoS One 2015;10:e0126324. 10.1371/journal.pone.0126324
    1. Ollevier A, Vanneuville I, Carron P. A 12-week multicomponent therapy in fibromyalgia improves health but not in concomitant moderate depression, an exploratory pilot study. Disabil Rehabil 2019;0:1–8.
    1. Martín J, Torre F, Padierna A, et al. . Six-and 12-month follow-up of an interdisciplinary fibromyalgia treatment programme: results of a randomised trial. Clin Exp Rheumatol 2012;30:103–11.
    1. Saral I, Sindel D, Esmaeilzadeh S, et al. . The effects of long- and short-term interdisciplinary treatment approaches in women with fibromyalgia: a randomized controlled trial. Rheumatol Int 2016;36:1379–89. 10.1007/s00296-016-3473-8
    1. Stein KF, Miclescu A. Effectiveness of multidisciplinary rehabilitation treatment for patients with chronic pain in a primary health care unit. Scand J Pain 2013;4:190–7. 10.1016/j.sjpain.2013.06.003
    1. Eisman AB, Kilbourne AM, Dopp AR, et al. . Economic evaluation in implementation science: making the business case for implementation strategies. Psychiatry Res 2020;283:112433. 10.1016/j.psychres.2019.06.008
    1. Anneliese P, Hoch J. Understanding cost-utility analysis in health care. Univ Toronto Med J 2006;83(2
    1. McGregor M. Cost-Utility analysis: use QALYs only with great caution. CMAJ 2003;168:433–4.
    1. Tarter T, Johnson G, Johnson R. Neuropsychology of Cancer and Oncology.. In: Noggle CA, Dean RS, eds. New York: Springer Publishing Company, 2013: 3–5.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe